Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully-integrated, commercial-stage biotechnology company, announced that its management team will participate in two investor conferences in August and September 2026. The company’s President and Chief Executive Officer, Dr. Seth Lederman, will engage with the investment community at these events, providing insights into the company’s business strategy and recent developments.
On August 11, Dr. Lederman will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston, scheduled from 1:30 p.m. to 1:55 p.m. ET. This session offers an opportunity for investors to hear directly from the CEO about Tonix’s progress and future plans. Additionally, on September 16, Dr. Lederman will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York. These meetings are designed to facilitate deeper discussions with key stakeholders and potential investors.
The participation in these conferences underscores Tonix’s commitment to maintaining transparent communication with the financial community. It also provides a platform to highlight the company’s recent achievements, particularly the approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), which represents the first new treatment for fibromyalgia in over 15 years. TONMYA is a flagship medicine for Tonix, and the company is actively exploring its full potential through Phase 2 clinical trials for major depressive disorder and acute stress disorder.
Beyond TONMYA, Tonix’s CNS portfolio includes acute migraine products such as Zembrace SymTouch and Tosymra, which are already marketed. The company is also developing TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. In the immunology space, Tonix is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection.
The company’s participation in these conferences is significant as it occurs at a pivotal time when Tonix is expanding its commercial infrastructure and advancing its pipeline. The events provide a venue for the company to articulate its vision and update investors on key milestones, which could influence investor sentiment and confidence. For stakeholders, these presentations offer a chance to gain clarity on the company’s strategic direction and the potential impact of its research on addressing unmet medical needs.
Tonix’s presence at these conferences also highlights the growing interest in central nervous system and immunology treatments, areas with high unmet medical needs. As the company continues to develop innovative therapies, its engagement with the investment community is crucial for securing support and fostering long-term growth. The conferences are expected to attract a wide range of healthcare investors, providing Tonix with valuable exposure.
For more information about Tonix Pharmaceuticals and its latest updates, visit the company’s newsroom at https://ibn.fm/TNXP.
